Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Apr;46(4):977-81.
doi: 10.1128/AAC.46.4.977-981.2002.

In vitro and in vivo activities of anti-influenza virus compound T-705

Affiliations

In vitro and in vivo activities of anti-influenza virus compound T-705

Y Furuta et al. Antimicrob Agents Chemother. 2002 Apr.

Abstract

T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has been found to have potent and selective inhibitory activity against influenza virus. In an in vitro plaque reduction assay, T-705 showed potent inhibitory activity against influenza A, B, and C viruses, with 50% inhibitory concentrations (IC(50)s) of 0.013 to 0.48 microg/ml, while it showed no cytotoxicity at concentrations up to 1,000 microg/ml in Madin-Darby canine kidney cells. The selectivity index for influenza virus was more than 2,000. It was also active against a neuraminidase inhibitor-resistant virus and some amantadine-resistant viruses. T-705 showed weak activity against non-influenza virus RNA viruses, with the IC(50)s being higher for non-influenza virus RNA viruses than for influenza virus, and it had no activity against DNA viruses. Orally administered T-705 at 100 mg/kg of body weight/day (four times a day) for 5 days significantly reduced the mean pulmonary virus yields and the rate of mortality in mice infected with influenza virus A/PR/8/34 (3 x 10(2) PFU). These results suggest that T-705 may be a compound that is useful and highly selective against influenza virus infections and that has a mode of action different from those of commercially available drugs, such as amantadine, rimantadine, and neuraminidase inhibitors.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Structure of T-705.
FIG. 2.
FIG. 2.
Effect of oral administration of T-705 on prevention of death in influenza virus-infected mice. Mice were infected with influenza virus A/PR/8/34 at 3 × 102 PFU/mouse as described in Materials and Methods. Mice were treated q.i.d. with oral doses of T-705 at 50 (▪), 100 (▴), or 200 (•) mg/kg/day or with methylcellulose solution as a control (○) for 5 days beginning 1 h after infection. The results presented here were obtained from a single representative experiment. ∗, P < 0.0125 compared to the results for 0.5% methylcellulose solution-treated controls (log rank test).
FIG. 3.
FIG. 3.
Effect of oral administration of T-705 on lung virus yield in influenza virus-infected mice. Mice were infected with influenza virus A/PR/8/34 at 3 × 102 PFU/mouse, and lung virus yields were determined as described in Materials and Methods. Mice were treated q.i.d. with oral doses of T-705 at 50, 100, or 200 mg/kg/day or with methylcellulose solution as a control for 5 days beginning 1 h after infection. The results presented here were obtained from a single representative experiment. The numbers in parentheses represent the number of mice whose lung virus titers were less than the limit of detection (2 × 102 PFU/lung). ∗, P < 0.05 compared to the results for 0.5% methylcellulose solution-treated controls (nonparametric Dunnett's test); ∗∗, P < 0.01 compared to the results for 0.5% methylcellulose solution-treated controls (nonparametric Dunnett's test).

Similar articles

Cited by

References

    1. Crotty, S., D. Maag, J. J. Arnold, W. Zhong, J. Y. N. Lau, Z. Hong, R. Andino, and C. E. Cameron. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379. - PubMed
    1. Dolin, R., C. R. Richard, M. H. Paul, M. Raina, N. L. Pamela, and W. J. Joan. 1982. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N. Engl. J. Med. 307:580-584. - PubMed
    1. Eggleston, M. 1987. Clinical review of ribavirin. Infect. Control 8:215-218. - PubMed
    1. Eriksson, B., E. Helgstrand, N. G. Johansson, A. Larsson, A. Misiorny, J. O. Noren, L. Philipson, K. Stenberg, G. Stening, S. Stridh, and B. Öberg. 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11:946-951. - PMC - PubMed
    1. Fiala, M., and G. Kenny. 1966. Enhancement of rhinovirus plaque formation in human heteroploid cell cultures by magnesium and calcium. J. Bacteriol. 92:1710-1715. - PMC - PubMed